bpc 157 limitless life nootropics #231 Dr. Kyle Gillett on Nootropics, Peptides, GLP-1 Side Effects, Hair Loss, and Microplastics BPC 157 (Body Protection Compound-157)

Clinical studies confirmed that the peptide produces no changes in serum IGF-1 levels, eliminating the appetite-stimulating effects associated with growth hormone therapy

If a peptide's manufacturer or supplier specifies a particular diluent, that guidance should always take priority over general defaults

The point is that MOTS-c's safety profile is harder to predict from first principles, and the data needed to narrow that uncertainty do not yet exist

its inhibition is studied for effects on NAD+ levels and adipocyte metabolism

Measure Subcutaneous half-life Published finding Not established in humans What it means Skipping the gut may change exposure, but no safe route conversion can be calculated from current data